Milestone Pharmaceuticals Inc. stock is down -3.14% since 30 days ago. The next earnings date is Mar 27, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 4 March’s closed higher than February. 100% of analysts rate it a buy.
Milestone Pharmaceuticals Inc. focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!